Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schering-Plough Gets CHMP Nod for Suboxone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Schering-Plough Gets CHMP Nod for Suboxone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough Corp. received recommendation for approval of Suboxone from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Suboxone sublingual tablets are for the substitution treatment of opioid dependence, within a framework of medical, social and psychological treatment.

Substitution treatment for opioid dependence is when opiate misuse is replaced with an oral opioid medication, such as buprenorphine or methadone, to deter intravenous misuse. Suboxone is intended for use in adults and adolescents 15 years of age and older who have agreed to be treated for addiction.

The CHMP recommendation will serve as the basis for a European Commission approval, which would result in Marketing Authorization with unified labeling valid in the 25 EU member states as well as in Iceland and Norway.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters